Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

SIGA Technologies

06/11/2025 21:13

Overview

SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year

Company attributes revenue decline to lower product sales, especially TPOXX deliveries

SIGA focuses on securing new procurement contracts for future revenue growth

Outlook

SIGA focuses on securing new procurement contracts for future revenue growth

Result Drivers

LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries

U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries

INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$6.40 mln


Analyst Coverage

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nGNX7g5NW3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)